Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
H. Lee Moffitt Cancer Center and Research Institute
iOnctura
Ipsen
Merck Sharp & Dohme LLC
Lokon Pharma AB
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Emory University
Hoffmann-La Roche
SWOG Cancer Research Network
Hoffmann-La Roche
Emory University
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
Merck Sharp & Dohme LLC
Corcept Therapeutics
GWT-TUD GmbH
Japan Breast Cancer Research Group
University of Iowa
Emory University
Merck Sharp & Dohme LLC
Jiangsu HengRui Medicine Co., Ltd.
University of Iowa
Abramson Cancer Center at Penn Medicine
Abramson Cancer Center at Penn Medicine
University of Colorado, Denver
Merck Sharp & Dohme LLC
Sun Yat-sen University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NGM Biopharmaceuticals, Inc
West China Hospital
University of California, San Francisco
University of Chicago
Pancreatic Cancer Action Network
Thomas Jefferson University
Herlev Hospital
Ohio State University Comprehensive Cancer Center
Columbia University
University of Michigan Rogel Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Orinove, Inc.
Washington University School of Medicine
Merck Sharp & Dohme LLC
Kyntra Bio
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
US Oncology Research
Merck Sharp & Dohme LLC
Emory University